Al-Sawaf O et al. Clonal dynamics after venetoclax-obinutuzumab therapy: Novel insights from the randomized, phase 3 CLL14 trial. ASH 2020;Abstract 127.
Brown JR et al. Pooled analysis of cardiovascular events from clinical trials evaluating acalabrutinib monotherapy in patients with chronic lymphocytic leukemia (CLL). ASH 2020;Abstract 3146.
Burger JA et al. Outcomes of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and high-risk genomic features with up to 6.5 years follow-up: Integrated analysis of two phase 3 studies (RESONATE-2 and iLLUMINATE). ASH 2020;Abstract 2220.
Crombie JL et al. Updated results from a phase I/II study of duvelisib and venetoclax in patients with relapsed or refractory CLL/SLL or Richter’s Syndrome. ASH 2020;Abstract 3141.
Davids MS et al. Updated safety and efficacy results from a phase 2 study of acalabrutinib, venetoclax and obinutuzumab (AVO) for frontline treatment of chronic lymphocytic leukemia (CLL). ASH 2020;Abstract 2216.
Ghia P et al. Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in relapsed/refractory chronic lymphocytic leukemia: Ascend final results. ASH 2020;Abstract 3140.
Kater AP et al. Five-year analysis of Murano study demonstrates enduring undetectable minimal residual disease (uMRD) in a subset of relapsed/refractory chronic lymphocytic leukemia (R/R CLL) patients (pts) following fixed-duration venetoclax-rituximab (VenR) therapy (tx). ASH 2020;Abstract 125.
Lansigan F et al. Subgroup analyses of elderly patients aged ≥ 70 years in MAGNIFY: A Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma. ASH 2020;Abstract 340.
Leslie LA et al. Clinical outcomes among real-world patients with chronic lymphocytic leukemia (CLL) initiating first-line ibrutinib or chemoimmunotherapy (CIT) stratified by risk status: Results from a US retrospective chart review study. ASH 2020;Abstract 372.
Mato AR et al. LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Results from the phase 1/2 BRUIN study. ASH 2020;Abstract 542.
Mato AR et al. Real-world prognostic biomarker testing, treatment patterns and dosing among 1461 patients (pts) with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the informCLL Prospective Observational Registry. ASH 2020;Abstract 547.
Woyach JA et al. Acalabrutinib in combination with venetoclax and obinutuzumab or rituximab in patients with treatment-naïve or relapsed/refractory chronic lymphocytic leukemia. ASH 2020;Abstract 1312.
Wierda WG et al. Ibrutinib (ibr) plus venetoclax (ven) for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 1-year disease-free survival (DFS) results from the MRD cohort of the phase 2 CAPTIVATE study. ASH 2020;Abstract 123.
Wierda WG et al. Transcend CLL 004: Phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). ASH 2020;Abstract 544.